Ministerio de Ciencia e Innovación (Espanya)
2012-09-05
The popularity of continuous subcutaneous insulin infusion (CSII), or insulin pump therapy, as a way to deliver insulin more physiologically and achieve better glycemic control in diabetes patients has increased. Despite the substantiated therapeutic advantages of using CSII, its use has also been associated with an increased risk of technical malfunctioning of the device, which leads to an increased risk of acute metabolic complications, such as diabetic ketoacidosis. Current insulin pumps already incorporate systems to detect some types of faults, such as obstructions in the infusion set, but are not able to detect other types of fault such as the disconnection or leakage of the infusion set
This work has been funded by the Wellcome Trust, the Spanish Ministry of Science and Innovation through grant DPI2010-20764-C02, the European Union through FEDER funds and Generalitat de Catalunya under grant 2009 SGR 523
Article
Accepted version
peer-reviewed
English
Medicaments -- Modes d'administració; Drug delivery systems; Insulina -- Administració; Insuline -- Administration; Diabetis -- Tractament; Diabetes -- Treatment; Control automàtic
Diabetes Technology Society
info:eu-repo/semantics/altIdentifier/doi/10.1177/193229681200600518
info:eu-repo/semantics/altIdentifier/issn/1932-2968
DPI2010-20764-C02-02
info:eu-repo/grantAgreement/MICINN//DPI2010-20764-C02-02/ES/NUEVAS ESTRATEGIAS DE CONTROL GLUCEMICO POSTPRANDIAL MEDIANTE TERAPIA CON BOMBA DE INSULINA EN DIABETES TIPO 1/
Tots els drets reservats